Document is current

Article History

Received: 27 March 2025

Accepted: 24 June 2025

First Online: 2 August 2025

Declarations

:

: Participation was approved by the local independent ethics committee or institutional review board as needed. A central ethics committee approval was provided by the sponsor, the University of Leipzig, under #288/22-ek.

: MH: research funding from Beigene and JanPix; consulting/advisory role for and honoraria from BeiGene, Janssen, Stemline Menarini, Takeda; honoraria also from Roche; expert testimony for Stemline Menarini; travel/accommodations and expenses from BeiGene, Janssen. EA: consulting/advisory role for Regeneron, Novartis; honoraria from Menarini-Stemline, BMS; travel/accommodations and expenses from AbbVie, Gilead; participation on a DSMB or advisory board for Vertex, BMS, Vifor. TMB: travel expenses for EBMT Congress 2024 from Neovii; honoraria from Vertex Pharmaceuticals. GR: research funding to institution from Syros (Site PI for SY-1425-301), Novartis (Site PI for CMBG 453B12203); travel accommodation for ASH 2022 from AbbVie. AC: advisory board for and honoraria from AbbVie, Pfizer, Novartis, Menarini-Stemline; honoraria also from BMS, Jazz Pharmaceuticals; DSMB for AbbVie, Novartis, Menarini-Stemline. KSG: advisory boards for and honoraria from AbbVie, BMS; honoraria from Jazz, BMS, Pfizer travel expenses for EHA 2023 from AbbVie. SW: consultancy for Stemline Therapeutics, AbbVie, AstraZeneca; honoraria from Lilly, Stemline Therapeutics; travel expenses from BeiGene, AbbVie. DE: no relevant conflicts of interest to disclose. MZ: employment with Menarini Group. ED: consultancy and honoraria for congress presentations from Stemline Menarini; travel accommodations/expenses from Novartis, Pfizer, Gilead, Janssen, AbbVie.

: Based on national or local institutional regulations for secondary use of data, if so required, patients consented to collection of their anonymized electronic health record data via the centrally approved informed consent form for this study.